Mounjaro approval expanded to reduce the risk of major cardiovascular events; The American Academy of Pediatrics has issued updated recommendations for RSV immunization; BTK inhibitor shows promise in ...

FDA clears Zanvastro (zilganersen) as the first disease-modifying therapy for Alexander disease following positive Phase 1-3 trial results.

FDA approves updated 2026-2027 COVID-19 vaccine formulations targeting the XFG variant for older adults and high-risk individuals.

HealthDay News — Paternal exposure to valproate during sperm development is not associated with neurodevelopmental disorders ...

Lisraya is the first oral dual TYK2/JAK1 inhibitor indicated for adults with dermatomyositis, demonstrating significant ...

HealthDay News — Baseline cortical atrophy measured within the early-onset Alzheimer disease (EOAD) signature, a set of ...

Interim Phase 1b/2a trial data support the MKK4 inhibitor's potential to protect hepatocytes and accelerate liver ...

Imaavy (nipocalimab-aahu) is the first FcRn blocker approved to treat warm autoimmune hemolytic anemia in patients aged 12 ...

Blood-based test identifies presence of amyloid plaques in symptomatic adults and is intended to be used in conjunction with a clinical assessment ...

Clinicians may not agree on physical exam findings for youth with community-acquired pneumonia (CAP), according to a study ...

Following Fast Track designation, a phase 2a trial will evaluate inhaled treprostinil (Yutrepia) as a potential first-in-class therapy for Raynaud phenomenon in systemic sclerosis.

Phase 3 RASolute 302 data show daraxonrasib significantly extended overall and progression free survival compared with ...